YAZ - Profile

US Patents and Regulatory Information for YAZ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	YAZ	drospirenone; ethinyl estradiol	TABLET;ORAL	021676-001	Mar 16, 2006	AB	RX	Yes	Yes

YAZ (drospirenone/ethinyl estradiol) Investment Scenario and Patent-Fueled Fundamentals Analysis (FY2020–FY2024)

Last updated: July 21, 2026

YAZ is a branded combined oral contraceptive (COC) with mature market exposure, limited near-term patent-led runway, and a regulatory and competitive profile dominated by generic COCs and label-positioning. The investment case is therefore driven less by exclusivity duration and more by (1) pricing power versus generic erosion, (2) channel dynamics in women’s health, and (3) any remaining exclusivity tied to specific dosage forms/packaging rather than blockbuster-scale pipeline optionality.

What patents protect YAZ (drospirenone/ethinyl estradiol) and how strong is the patent estate?

Short answer: YAZ’s core protection is not a live, multi-decade asset in most jurisdictions; the economics have largely moved into a generic-competition regime. The investable value is mainly packaging/label protection and any remaining life-cycle patents covering formulation, manufacturing, or specific uses, not primary compound discovery.

Core IP typically relevant to COCs: what to look for

For YAZ-type COCs, patent estates usually cluster into:

• Combination composition (drospirenone + ethinyl estradiol ratios and dosage regimen)
• Method of use (contraception and secondary indications such as acne)
• Formulation and manufacturing (tablet composition, stability, manufacturing processes)
• Regimen/IP around 24/4 dosing (though dosing regimens can be more easily designed around)

How to underwrite “estate strength” for YAZ

Investment-grade underwriting for an off-patent COC generally focuses on:

• Whether any later-life formulation/manufacturing patents still appear in the Orange Book for the specific NDCs used in the US
• Whether litigation created staying power for any authorized generic or launch timing
• Whether exclusivity (not patents) still applies for a specific change to the product

What this means for investors

In YAZ, the relevant conclusion for fundamentals is simple: absent a clearly identified, enforceable end-of-life patent that maps to current product NDCs, the asset’s value decays with generic supply and price competition. A premium franchise can still exist, but it is rarely patent-driven at this stage.

When does YAZ lose exclusivity, and what drives the actual timeline to generic erosion?

Short answer: For marketed COCs like YAZ, generic entry tends to follow a combination of patent expiry, any relevant regulatory exclusivity, and the practical realities of generic approvals plus pharmacy wholesaler formularies.

Exclusivity in a COC context

Two time-structures matter in underwriting:

1. Patent expiration (hard end to exclusivity)
2. Regulatory market events after that (generic approvals, authorized generic availability, and formulary switching)

Investment-relevant timeline mechanics

• Generic manufacturers can often bring bioequivalent products quickly after patent and/or exclusivity clearance.
• Price compression is then channel-driven. Even if the initial generic wave is slower in some formularies, national erosion typically follows.

What is the Orange Book status of YAZ, and which patents are listed per active ingredient/NDC?

Short answer: YAZ’s Orange Book listing status determines whether any listed patents could still block generic entry for specific NDCs, but the overall economics usually indicate that the main protection is already exhausted.

Orange Book underwriting checklist

For YAZ, investment diligence should map:

• Listed patents by active ingredient and dosage form
• Patent expiration dates and patent listing codes (e.g., composition vs method-of-use)
• Whether any listed patents are held up by ongoing litigation (rare after the product is long mature, but it can occur for life-cycle items)

Why this matters

• If only residual patents remain, the investment case becomes pricing and distribution, not exclusivity.
• If an unexpectedly late patent is listed for the specific NDCs still generating sales, you can model a delayed generic risk scenario.

How many ANDA/generic products compete with YAZ, and what generic entry risks exist?

Short answer: YAZ’s market exposure is generally characterized by heavy generic penetration typical for COCs with established bioequivalent pathways.

Generic entry risk drivers for YAZ

• ANDA approvals for bioequivalent drospirenone/ethinyl estradiol tablets
• Formulary substitution and pharmacy switching at scale
• Wholesale stocking patterns that normalize lower-price offerings
• Authorized generic dynamics following litigation or settlement events in some cases

What investors should model

• A post-clearance margin step-down (wholesale and pharmacy reimbursement pressure)
• A potential volume shift into lowest-cost generics
• Residual retention if prescribers prefer specific product attributes (tolerability perceptions, continuity of care, or patient adherence)

Which companies challenge YAZ with Paragraph IV ANDAs, and what patent litigation affects YAZ?

Short answer: Paragraph IV challenges for mature COCs tend to be episodic rather than continuous. For YAZ, the practical impact on the investment case is whether any litigation created delays beyond the statutory clearance date.

Litigation outcome mechanics that affect returns

For COCs, market impact usually comes from:

• Injunctions that delay generic supply
• Settlement terms that shift launch timing
• Authorized generic provisions that prevent full price normalization

Investment modeling approach

• Base case: generic launches proceed on clearance
• Downside: delayed clearance or partial settlements postpone price erosion
• Upside: faster-than-modeled generic normalization with aggressive payer adoption

What formulations are protected by YAZ patents, and can competitors design around?

Short answer: Formulation patents matter mainly when they create meaningful differences in stability, release profile, or manufacturing yield that support premium pricing. For COCs, many formulation elements are design-around friendly.

Design-around reality for COCs

Competitors can often pursue:

• Equivalent tablet composition at the level needed for bioequivalence
• Different excipient sets that still meet stability and dissolution specs
• Process changes that avoid manufacturing-process patents

Investment implication

Unless YAZ’s remaining patents are clearly tied to non-design-aroundable features for current NDCs, competitors can usually match.

How does YAZ compare with other drospirenone/ethinyl estradiol COCs in patent and commercial risk?

Short answer: In the drospirenone/ethinyl estradiol segment, clinical interchangeability and generic bioequivalence reduce patent-driven differentiation. Commercial performance differences mostly reflect brand strength, payer contracting, and prescriber habits.

Comparative lens that matters

• Where each product sits on formularies
• Contracted net pricing vs gross margin impact
• Patient adherence outcomes that may keep a brand “preferred” in specific plans even after generic availability

Is YAZ exposed to biosimilar or biologic-style IP risk?

Short answer: No. YAZ is a small-molecule oral contraceptive, not a biologic. It is not exposed to biosimilar pathways.

Why this matters for investors

The risk framework is ANDA-centric, not BLA/biosimilar-centric:

• Patent expiry
• Orange Book listings
• ANDA filing and approval timing
• Litigation/settlement-driven delays

What is the FDA regulatory status of YAZ, and what does it mean for market access and exclusivity?

Short answer: YAZ is an approved COC; regulatory status impacts generic substitution via the ANDA pathway and any relevant listed-patent barriers.

Underwriting market access

For investors, FDA status translates to:

• How quickly generics can approve
• Whether reformulations or labeling changes occurred that could refresh exclusivity (usually limited for mature COCs)

What revenue exposure does YAZ face from generic competition, and how should investors model net sales?

Short answer: Net sales exposure is typically dominated by price compression after generic penetration, with volume retention depending on payer and prescriber behavior.

Model structure

• Start with forecasted prescriptions (segment-level women’s health trends)
• Apply a net price curve: rapid compression post-generic entry, followed by stabilization at a lower band
• Apply payer mix: Medicaid and large PBM formulary penetration tends to accelerate generic adoption
• Apply gross-to-net: rebates and incentives may intensify with increased generic competition

Investment-grade metrics to track

• Gross margin trend
• Market share erosion velocity post-generic
• Net price changes at major customers and PBMs
• Shelf availability and wholesaler replenishment behavior

How strong is the patent estate for YAZ versus other mature branded COCs?

Short answer: For most mature branded COCs, the patent estate does not materially extend brand life beyond the period when generics can launch. The strongest “IP” tends to be residual listed patents paired with channel contracts, not primary compound coverage.

Practical comparison

• Stronger estates show delayed generic launches due to enforceable patents still active for current NDCs.
• Weaker estates show generic launches proceed and brand economics are mostly channel-dependent.

What commercialization strategies can defend YAZ economics after generic entry?

Short answer: The defensive strategies for COCs usually revolve around contracting, patient continuity, and specialty targeting rather than IP.

Common levers

• Maintain strong payer positioning via net price and rebate terms
• Support prescriber preference via patient adherence and continuity programs
• Target patient cohorts less likely to switch due to tolerability history
• Use packaging and product support to reduce switching friction

Key Takeaways

• YAZ’s investment case is primarily pricing and channel economics rather than patent-driven growth, given the mature, small-molecule COC profile.
• The main diligence question is whether any enforceable, NDC-specific Orange Book-listed patents or exclusivities still meaningfully delay generic substitution.
• Generic entry risk is structured through ANDA approvals and formulary switching; litigation matters mainly if it created launch timing delays or settlement-driven barriers.
• For modeling, focus on a net price curve post-competition and prescription retention dynamics by payer segment.

FAQs

1. How do Orange Book “listed patents” for COCs affect ANDA approval timing for products like YAZ?
2. What is the difference between patent expiration and market erosion in generic COCs?
3. How do PBM formularies and rebates influence YAZ net pricing after generic entry?
4. Do life-cycle formulation patents for oral contraceptives materially delay generic substitution?
5. What indicators best predict how fast YAZ prescriptions shift to drospirenone/ethinyl estradiol generics?

References

(No sources were cited because the required factual inputs, such as YAZ Orange Book listings, specific patent numbers, litigation docket details, and FDA status artifacts, were not provided in the prompt.)